TOKYO and XIAMEN, February 23, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that an application for partial revision of manufacturing and marketing approval for AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”), an in vitro diagnostic reagent for multiple antineoplastic agents, was submitted in February 2022 (hereinafter referred to as the "Application for Partial Change")
Read the full press release below:
2-23-22 JointRelease_ROS1_Entrectinib_FINAL
.pdf
Download PDF • 267KB